Regeneron Pharmaceuticals Inc REGN:NASDAQ

Last Price$286.15NASDAQ Closing Price as of 3:59PM ET 9/19/19

Today's Change+1.09(0.38%)
Bid (Size)$281.15 (7)
Ask (Size)$289.00 (1)
Day Low / High$284.66 - 287.95
Volume421.1 K

View Biotechnology IndustryPeer Comparison as of 09/19/2019


Regeneron Pharmaceuticals Inc ( NASDAQ )

Price: $286.15
Change: +1.09 (0.38%)
Volume: 421.1 K
3:59PM ET 9/19/2019

Agilent Technologies Inc ( NYSE )

Price: $78.06
Change: +0.49 (0.63%)
Volume: 1.8 M
3:59PM ET 9/19/2019

Alexion Pharmaceuticals Inc ( NASDAQ )

Price: $105.67
Change: +2.69 (2.61%)
Volume: 2.2 M
4:00PM ET 9/19/2019

Biogen Inc ( NASDAQ )

Price: $235.60
Change: +0.43 (0.18%)
Volume: 1.3 M
4:00PM ET 9/19/2019

Illumina Inc ( NASDAQ )

Price: $305.20
Change: +2.19 (0.72%)
Volume: 794.8 K
4:00PM ET 9/19/2019

Read more news Recent News

Insider Makes Significant Stock Sells in Regeneron Pharmaceuticals (REGN) Shares
10:17PM ET 9/13/2019 MT Newswires

There was a notable sale of shares of Regeneron Pharmaceuticals by an insider today, as revealed in a form 4 document filed with the SEC. One insider --...

Insider Trends: Insider 90-Day Selling Trend Extended at Regeneron Pharmaceuticals
5:02PM ET 9/12/2019 MT Newswires

Sanofi, 10% Owner, on Sep 10, 2019, sold 172,904 shares in Regeneron Pharmaceuticals (REGN) for $48,611,804. Subsequent to the Form 4 filing with the SEC,...

Regeneron Pharmaceuticals, Sanofi Win Court Ruling in Patent Case Against Amgen
5:11PM ET 8/28/2019 MT Newswires

Regeneron Pharmaceuticals (REGN) and Sanofi said that a federal court ruled that Amgen's (AMGN) patent claims were invalid in litigation against the drug...

Regeneron Pharmaceuticals Says Trial Shows Efficacy in Genetic Cholesterol Disorder Treatment
11:47AM ET 8/14/2019 MT Newswires

Regeneron Pharmaceuticals (REGN) said it achieved positive phase 3 trial results for evinacumab, a monoclonal antibody that specifically binds to...

View all Commentary and Analysis

Regenxbio And RGX-501 In Homozygous Familial Hypercholesterolemia
25 minutes ago, 8:44PM ET 9/19/2019 Seeking Alpha

Healthcare And Biotechnology Dashboard - Update
2:10AM ET 9/18/2019 Seeking Alpha

Why Regeneron Is Still A Deep Value Play
5:15AM ET 9/17/2019 Seeking Alpha

IPO Update: IGM Biosciences Files For $125 Million IPO
12:47PM ET 9/09/2019 Seeking Alpha

Company Profile

Business DescriptionRegeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY. View company web site for more details
Address777 Old Saw Mill River Road
Tarrytown, New York 10591-6707
Number of Employees7,400
Recent SEC Filing09/12/20194
Co-President, Chief Executive Officer & DirectorLeonard S. Schleifer
Co-President, Director & Chief Scientific OfficerGeorge Damis Yancopoulos
Chief Financial Officer & Executive VP-FinanceRobert E. Landry
Chief Compliance Officer & Senior Vice PresidentBeth F. Levine

Company Highlights

Price Open$284.66
Previous Close$285.06
52 Week Range$271.57 - 442.00
Market Capitalization$30.9 B
Shares Outstanding108.0 M
SectorHealth Technology
Next Earnings Announcement11/05/2019

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings15.65
Earnings per Share$18.80
Beta vs. S&P 500N/A
Revenue$6.7 B
Net Profit Margin28.59%
Return on Equity23.10%

Analyst Ratings as of 08/30/2019

Consensus RecommendationConsensus Icon
Powered by Factset